Benefits
Body weight reduction over 28 days
In a randomized, double-blind, placebo-controlled trial run with researchers from the maker, adults with a BMI of 25 or more lost about 3.6 kg on 100 mg and 4.6 kg on 200 mg a day over 28 days, while the placebo group gained about 2 kg. A smaller maker-run trial of 200 mg found a 2.1% weight drop. Losses this fast are unusual and have not been confirmed by independent researchers.
Increased energy expenditure
Energy expenditure measured at rest after exercise rose by about 195 kcal on 100 mg and 300 kcal on 200 mg in the Capsifen trial, compared with a small fall on placebo. Independent pooled trials of capsaicinoids and related capsinoids found a much smaller rise in resting metabolic rate, about 34 kcal a day.
Fat oxidation (lower respiratory quotient)
Respiratory quotient, a breath measure of whether the body is burning more fat or carbohydrate, fell about 4% on 100 mg and 11% on 200 mg compared with baseline, and both differed from placebo at the end of the 28-day trial. Independent pooled trials of capsaicinoids also found a small shift toward fat oxidation.
Endurance: longer time to exhaustion
In the 28-day trial, time to exhaustion in a maximal treadmill test rose about 69% on 100 mg and 56% on 200 mg compared with baseline, with no change on placebo. This comes from one maker-linked trial, and the authors list the self-selected treadmill speed as a limitation.
Slow-release form with masked pungency
FenuMat beadlets of fenugreek fiber hold the capsaicinoids so they are released in the intestine rather than the stomach, which is meant to avoid the burning taste of chili extract. A small trial detected capsaicinoids in blood after 200 mg a day, but no published human study has compared Capsifen's absorption with a standard chili extract.
Tolerability: no change in heart rate or blood pressure
Heart rate and blood pressure did not change over 28 days at either dose, and no one reported palpitations. Four people on 200 mg had abdominal pain in the first 3 days and 2 had diarrhea that settled within a week; the authors advise against taking it on an empty stomach.
Mechanism of action
TRPV1 receptor activation (thermogenesis)
Capsaicinoids activate TRPV1, a heat-sensing channel on sensory nerves. This triggers sympathetic nervous system activity, which can raise heat production and energy expenditure; pooled human trials show a small rise in resting metabolic rate.
Fat oxidation
In animal studies, capsaicinoids increase the activity of fat-burning enzymes and reduce fat storage. In people, the Capsifen trial measured only breath-based fuel use (respiratory quotient), which shifted toward fat.
Catecholamine release
Sympathetic activation releases noradrenaline and adrenaline, which free fatty acids from fat tissue for use as fuel. Caffeine also raises sympathetic activity, but by a different route (adenosine receptor blocking) rather than TRPV1.
FenuMat slow intestinal release
Fenugreek galactomannan beadlets form a gel that is designed to release capsaicinoids in the small intestine rather than the stomach, where direct capsaicin contact causes the familiar burn.
Clinical trials
Randomized, double-blind, placebo-controlled, three-arm parallel trial: placebo, 100 mg or 200 mg a day for 28 days; two authors were employed by the maker and one by the contract research firm that ran it (Roopashree et al. 2024, Front Nutr).
105 adults aged 21 to 45 with a BMI of 25 or more enrolled; 94 analysed.
Resting and post-exercise energy expenditure rose and respiratory quotient fell in both Capsifen groups versus placebo. Weight went from about 75.1 to 71.5 kg on 100 mg and 75.3 to 70.7 kg on 200 mg, while placebo went from 74.3 to 76.5 kg. Time to exhaustion rose 69% and 56% from baseline. Heart rate and blood pressure did not change. Some on 200 mg had abdominal pain early on, and 2 had short-lived diarrhea.
Randomized, double-blind, placebo-controlled pilot trial of 200 mg a day (about 4 mg capsaicinoids) for 28 days, by researchers from the maker (Joseph et al. 2021, J Diet Suppl).
24 adults with overweight (12 per group).
Body weight fell 2.1%, BMI 2.2% and waist-to-hip ratio 4% versus placebo, and questionnaire scores for uncontrolled eating and appetite improved. Capsaicinoids were detected in blood. No adverse events or changes in blood safety tests were reported.